Tradestie Institutional Equity Comparison Engine
BOLD vs CBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BOLD Overall Edge
BOLD Captures Institutional Edge (3โ0 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BOLD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BOLD N/M vs CBIO N/M Fwd P/E
Growth & Margin Winner
BOLD
Op Margin 0.0% vs -1228.4% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
BOLD
1Y +101.7% vs -0.2% ยท 52W Pos 62% vs 23%
Options & Structure Winner
BOLD
UNCLASSIFIED (N/A IV) vs BREAKDOWN (98th %ile IV)
BOLD
NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap
$56.2M
1M Return
-4.92%
1Y Return
+101.74%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 25.0
Fund 50.0
Flow 50.0
Mom 60.0
CBIO
NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap
$539.5M
1M Return
-1.07%
1Y Return
-0.23%
Forward P/E
N/M
Unified AI Score
49.2 / 100
HOLD
Tech 45.0
Fund 56.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BOLD +101.74%
CBIO -0.23%
Spread: +101.97 pp (BOLD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BOLD TTM Op. Margin: 0.0%
CBIO TTM Op. Margin: -1228.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs CBIO. Trailing 12-month operating profitability (BOLD 0.0% vs CBIO -1228.4%) and valuation multiples (BOLD N/M vs CBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BOLD | CBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $56.2M | $539.5M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | -1228.4% | Higher Margin | BOLD |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -64.6% | -160.8% | Higher ROE | BOLD |
| 52-Week Range Position Momentum | 62% ($1โ$3) | 23% ($9โ$27) | Stronger Trend | BOLD |
| Beta / 30D Volatility Risk Regime | -0.08ฮฒ ยท 28% Vol | 1.18ฮฒ ยท 60% Vol | Lower Realized Risk | BOLD |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 49.2 / 100 (HOLD) | Higher Composite | CBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BOLD vs CBIO Buy Guide
BOLD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CBIO
BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
98th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BOLD nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.